drugset

drugset / Trial / NCT04947345

The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients

NCT04947345 ↗

Phase 3 Unknown 84 enrolled Peking Union Medical College Hospital Yichang Humanwell Pharmaceutical Co., Ltd., China · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This trial intends to evaluate Remimazolam Besylate's availability and safety compared with propofol.

Timeline

Start: 2021-09-01
Primary completion: 2022-03-01
Completion: 2022-09-01

Publications

Liu S, Su L, Zhang B, He H, Li Z, Li Q, Wang Q, Smith F, Long Y. The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients Under Mechanical Ventilation in ICU: Protocol for a Randomized, Open-Label, Controlled Trial. Front Med (Lausanne). 2021 Nov 5;8:735473. doi: 10.3389/fmed.2021.735473. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Propofol	Small molecule	—	Intravenous
Subject	Remimazolam	Small molecule	—	—

Indications

No indication recorded.